$CYTH
Cyclo Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000143774923014257 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $117.1K $152.4K $186.8K
YoY Change -78.39% -21.8% -68.07%
Cost Of Revenue $26.97K $11.45K $16.61K
YoY Change -65.13% -44.93% -77.44%
Gross Profit $90.15K $141.0K $170.2K
YoY Change -80.59% -19.04% -66.73%
Gross Profit Margin 76.97% 92.49% 91.11%
Selling, General & Admin $1.548M $1.745M $1.963M
YoY Change -24.17% -13.6% 4.09%
% of Gross Profit 1717.22% 1238.02% 1153.58%
Research & Development $3.170M $3.398M $3.185M
YoY Change 69.13% 213.47% 125.18%
% of Gross Profit 3516.58% 2410.73% 1871.41%
Depreciation & Amortization $4.820K $4.819K $4.870K
YoY Change 1.69% 1.65% 15.68%
% of Gross Profit 5.35% 3.42% 2.86%
Operating Expenses $3.170M $3.398M $5.153M
YoY Change 69.13% 213.47% 55.93%
Operating Profit -$4.633M -$5.007M -$4.983M
YoY Change 34.05% 70.63% 78.39%
Interest Expense -$3.510K $50.00 $2.480K
YoY Change -187.1% -98.85% 166.67%
% of Operating Profit
Other Income/Expense, Net -$3.513K $47.00
YoY Change -187.08% -99.97%
Pretax Income -$4.636M -$5.007M -$4.980M
YoY Change 34.31% 80.66% 78.36%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.636M -$5.007M -$4.980M
YoY Change 34.31% 80.66% 78.36%
Net Earnings / Revenue -3958.79% -3285.25% -2666.18%
Basic Earnings Per Share -$0.33 -$0.46
Diluted Earnings Per Share -$0.33 -$0.46 -$0.59
COMMON SHARES
Basic Shares Outstanding 15.17M 10.55M 8.482M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $841.5K $915.2K $1.543M
YoY Change -88.71% -92.24% -90.71%
Cash & Equivalents $841.5K $915.2K $1.543M
Short-Term Investments
Other Short-Term Assets $3.381M $2.703M $2.306M
YoY Change -6.7% -26.42% 12.08%
Inventory $236.6K $244.5K $254.5K
Prepaid Expenses
Receivables $88.39K $131.2K $54.99K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.548M $3.993M $4.159M
YoY Change -61.38% -74.81% -78.6%
LONG-TERM ASSETS
Property, Plant & Equipment $45.55K $50.37K $55.19K
YoY Change -16.73% -15.26% -7.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $94.70K $103.8K $56.66K
YoY Change 46.18% 40.35% -32.95%
TOTAL ASSETS
Total Short-Term Assets $4.548M $3.993M $4.159M
Total Long-Term Assets $94.70K $103.8K $56.66K
Total Assets $4.643M $4.097M $4.215M
YoY Change -60.79% -74.27% -78.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.078M $4.483M $3.481M
YoY Change 190.54% 56.65% -5.36%
Accrued Expenses $17.47K $16.97K $0.00
YoY Change 78.08% 16.55% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.096M $4.500M $3.481M
YoY Change 190.02% 56.44% -9.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $31.94K $36.53K
YoY Change
Total Long-Term Liabilities $31.94K $36.53K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.096M $4.500M $3.481M
Total Long-Term Liabilities $31.94K $36.53K $0.00
Total Liabilities $6.128M $4.536M $3.481M
YoY Change 191.54% 57.71% -9.57%
SHAREHOLDERS EQUITY
Retained Earnings -$73.44M -$68.81M -$63.80M
YoY Change 34.58% 34.6% 31.96%
Common Stock $1.531K $1.056K $849.00
YoY Change 81.4% 25.42% 0.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.485M -$438.9K $734.5K
YoY Change
Total Liabilities & Shareholders Equity $4.643M $4.097M $4.215M
YoY Change -60.79% -74.27% -78.41%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.636M -$5.007M -$4.980M
YoY Change 34.31% 80.66% 78.36%
Depreciation, Depletion And Amortization $4.820K $4.819K $4.870K
YoY Change 1.69% 1.65% 15.68%
Cash From Operating Activities -$3.479M -$4.370M -$2.747M
YoY Change -20.14% -9.52% 5.17%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.405M $3.742M 0.000
YoY Change 55107.98% -100.0%
NET CHANGE
Cash From Operating Activities -3.479M -$4.370M -2.747M
Cash From Investing Activities 0.000 $0.00 0.000
Cash From Financing Activities 3.405M $3.742M 0.000
Net Change In Cash -73.65K -$628.2K -2.747M
YoY Change -98.31% -86.95% -133.61%
FREE CASH FLOW
Cash From Operating Activities -$3.479M -$4.370M -$2.747M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.479M -$4.370M -$2.747M
YoY Change -20.14% -9.61% 5.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8481848
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8481848
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10053544
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10053544
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-25466
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3029743
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6714 NW 16th Street, Suite B
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Gainesville
CY2023Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
1252 usd
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32653
CY2023Q1 dei City Area Code
CityAreaCode
386
CY2022Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
4323 usd
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
418-8060
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15168397
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
915176 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1543418 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
131224 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54991 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
244497 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
254491 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
188638 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
101135 usd
CY2023Q1 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
2513923 usd
CY2022Q4 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
2204520 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
3993458 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
4158555 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50369 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55188 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53393 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1470 usd
CY2023Q1 us-gaap Assets
Assets
4097220 usd
CY2022Q4 us-gaap Assets
Assets
4215213 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16969 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4482600 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3480669 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4499569 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3480669 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36527 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
36527 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1056 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
849 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68366532 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64533074 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68806464 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63799379 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-438876 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
734544 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4097220 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4215213 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
152411 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
194904 usd
CY2023Q1 us-gaap Salaries And Wages
SalariesAndWages
906955 usd
CY2022Q1 us-gaap Salaries And Wages
SalariesAndWages
1216905 usd
CY2023Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
10196 usd
CY2022Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
16464 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3398167 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1084052 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
482835 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
412055 usd
CY2023Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
282375 usd
CY2022Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
294176 usd
CY2023Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
72125 usd
CY2022Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
92125 usd
CY2023Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
4819 usd
CY2022Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
4741 usd
CY2023Q1 ctdh Freight And Shipping
FreightAndShipping
819 usd
CY2022Q1 ctdh Freight And Shipping
FreightAndShipping
4520 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
5159543 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
3129361 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5007132 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2934457 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4342 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
162866 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5007085 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2771591 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5007085 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2771591 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11003588
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8411798
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
734544 usd
CY2023Q1 ctdh Stock Issued During Period Value Common Stock And Prefunded Warrants
StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants
3741883 usd
CY2023Q1 ctdh Stock Issued During Period Value Warrants
StockIssuedDuringPeriodValueWarrants
114 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91668 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5007085 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-438876 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15671863 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106738 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2771591 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13048014 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5007085 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2771591 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4819 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4741 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
158524 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91668 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
106738 usd
CY2023Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
0 usd
CY2022Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
41004 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
76233 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-374738 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9994 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6381 usd
CY2023Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
309403 usd
CY2022Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
1426434 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
87503 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
189368 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1573 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1537 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1001931 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-816397 usd
CY2023Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
636846 usd
CY2022Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-2058658 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4370239 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4830249 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4600 usd
CY2023Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-0 usd
CY2022Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-13916 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9316 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2407849 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1334034 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
114 usd
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2023Q1 ctdh Proceeds From Issuance Repayments Of Longterm Debt
ProceedsFromIssuanceRepaymentsOfLongtermDebt
0 usd
CY2022Q1 ctdh Proceeds From Issuance Repayments Of Longterm Debt
ProceedsFromIssuanceRepaymentsOfLongtermDebt
-8159 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3741997 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6778 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-628242 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4814155 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1543418 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16612711 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
915176 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11798556 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1730 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
10300 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52900 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(q) USE OF ESTIMATES––The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to inventory obsolescence, stock-based compensation and warrant liability valuation. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.</p>
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5007085 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68806464 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4370239 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
915176 usd
CY2023Q1 ctdh Working Capital Deficit
WorkingCapitalDeficit
506100 usd
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
152411 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
194904 usd
CY2023Q1 ctdh Operating Lease Right Of Usse Asset Amortization
OperatingLeaseRightOfUsseAssetAmortization
4256 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
9535 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
7397 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
321631
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5007085 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2771591 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11003588
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
8411798
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46

Files In Submission

Name View Source Status
ctdh-20230331_cal.xml Edgar Link unprocessable
0001437749-23-014257-index-headers.html Edgar Link pending
0001437749-23-014257-index.html Edgar Link pending
0001437749-23-014257.txt Edgar Link pending
0001437749-23-014257-xbrl.zip Edgar Link pending
ctdh-20230331.xsd Edgar Link pending
ctdh20230331_10q.htm Edgar Link pending
ex_515018.htm Edgar Link pending
ex_515019.htm Edgar Link pending
ex_515020.htm Edgar Link pending
ex_515021.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
ctdh-20230331_pre.xml Edgar Link unprocessable
ctdh-20230331_lab.xml Edgar Link unprocessable
ctdh-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctdh20230331_10q_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending